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Organ transplantation is currently the standard therapy for patients with end-stage organ dysfunction. The 
immunosuppression caused by this therapy increases the rate of infection, particularly in the lungs. Early diagnosis 
is extremely important and fibre-optic bronchoscopy is a helpful tool in reaching diagnosis. Knowing the timing of 
various pathogens following transplantation, and the radiological picture as well as the prophylactic regimen, is 
helpful when specific pathogens are suspected. Bronchoscopy with bronchoalveolar lavage and transbronchial 
biopsies are particularly helpful in diagnosis of bacterial cytomegalovirus (CMV) and pneumocytosis carinii 
pneumocytosis, and is considered a safe procedure. Open lung biopsy is reserved for those who have negative 
bronchoscopy with a reasonable prognosis. 
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Introduction 
In the last decade an increasing number of immunocom- 
promised patients have come to medical attention because 
of pulm,onary infiltrates of various aetiologies. Solid organ 
transplant recipients form an important and an increasingly 
growing subgroup of immunocompromised patients. 
Transplant patients may present at any time interval after 
the transplant with infections caused by bacteria, viruses, 
parasites or ftingi. In making the clinical decisions 
regarding the investigation and the management of these 
patients, different factors should be taken into account such 
as the type of immunosuppression, the transplanted organ 
adjacent to which the infectious process is taking place 
and the timing of the appearance of pulmonary infiltrates 
following the transplant. ‘Moreover, as the lung is exposed 
to the immediate surrounding environment, it is more 
likely to be exposed to infectious pathogens from the 
environment, particularly in lung transplant patients as 
the transplanted lung is markedly vulnerable to such 
infections. 
As a result of immunosuppressive therapy, the clinical 
manifestations of pulmonary infections in the transplant 
patient may be variably attenuated (e.g., corticosteroids 
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decrease fever and azathioprine may induce leukopaenia). 
Similarly, the spectrum of roentgenographical findings is 
not different from normal hosts and may include lobar or 
localized infiltrates which may contain cavitations as in 
fungal pneumonia, or interstitial infiltrates common in 
other opportunistic infections such as Cytomegalovirus 
(CMV) pneumonitis and Pneumocystis carinii pneumonitis 
(PCP). The finding of pulmonary infiltrates on chest x-ray 
films may be otherwise explained by pulmonary congestion, 
embolism or alveolar haemorrhage. It is most important to 
recognize pulmonary infections as they carry a great risk 
for morbidity and mortality in these patients. 
The role of conventional methods of diagnosing pneu- 
monia in the immunocompromised host are limited. The 
serological methods for the diagnosis of viral pneumonias 
such as caused by CMV have low sensitivity and specificity 
in the immunocompromised host because of decreased 
antibody production, due to immune suppression (1). The 
yield of sputum staining and culture in normal hosts is 
usually low, especially in atypical pneumonia. Therefore, 
many immunocompromised patients who are more likely to 
present with atypical pneumonias do not produce sufficient 
sputum to allow identification of a bacterial or other 
pathogen. 
The purpose of this review is to describe the current 
knowledge regarding the diagnostic yield of fibre-optic 
bronchoscopy (FOB) when utilized for thi investigation of 
pneumonias in solid organ transplant patients. Emphasis 
will be put on opportunistic pathogens such as Pneumo- 
cystis carinii and CMV, which are unique pathogens in 
these patients. .> 
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FIG 1. The incidence of specific pulmonary pathogens in ( q , bacterial; H, viral/CMV; q J, PCP; q fungal) organ transplant 
recipients at various time intervals after transplantation (incidence is described as events patient-’ year-‘) (3,4,8,73). (a) 
Heart-lung transplantation; (b) liver transplantation; (c) heart transplantation; (d) kidney transplantation. 
Timing and types of various Special considerations in lung and 
infections in organ transplantation heart-lung recipients 
In order to evaluate the role of FOB for pulmonary 
infiltrates in solid organ recipients, the types and timing 
of the various infections after transplant should be 
considered. 
Pulmonary infections in organ transplant patients are 
mostly caused by bacterial pathogens. During the first l-2 
months after transplantation, there is a higher incidence of 
bacterial pneumonias caused by hospital-acquired patho- 
gens (Gram-negative rods, staphylococci or Legionella 
pneurnophila), but in later stages pneumonia may be caused 
by community-acquired pathogens, such as Streptococcus 
pneumoniae or Mycoplasma pneumoniae (2). During the 
time interval of 2-4 months post-transplantation, there is a 
significant increase in the incidence of CMV-induced 
pneumonitis (Fig. 1). Additionally, there is a rise in the 
rate of fungal infections with an epidemiology which may 
partly reflect the incidence of endemic fungal infections, but 
also an increasing incidence of invasive Candida species and 
Aspergillosis infections. The incidence of PCP increases 
significantly 2-3 months post-transplantation and remains 
high during the first 6 months after transplantation. The 
differential diagnosis of new-onset pulmonary infiltrates in 
organ transplant patients also includes tuberculosis, 
nocardiosis, and malignant processes such as lymphoma 
and Kaposi’s sarcoma. 
Infections involving the grafted lung in lung and heart-lung 
transplant recipients deserve special consideration. The 
susceptibility of the grafted lungs to infections results from 
local factors such as changes in the lymphatic drainage of 
the lungs. Denervation of the lungs and the anastomosis 
itself suppress the cough reflex, thus masking symptoms 
of pulmonary infection (3). Of the local immunological 
factors which affect the grafted lung, immune suppression 
plays a central role as a risk factor for bacterial and 
opportunistic pneumonia, as it increases the vulnerability 
of the grafted lung to pathogens. Additionally, allograft 
rejection can cause lung injury, leading to further damage 
to lung tissue structure such as the tendency to develop 
bronchiectasis in patients with post-transplant bronchiolitis 
obliterans, thus adding significant risk for infection. More- 
over, in patients with a single lung transplantation, the 
remaining lung may serve as a source of infection. Similar 
to the sinuses in patients with cystic fibrosis. 
All these factors explain the higher rate of pulmonary 
infection in patients after heart-lung transplantation than 
after heart transplantation alone (4). Accordingly, lung 
and heart-lung transplant recipients not only have a higher 
incidence of bacterial pneumonia, but also of CMV 
pneumonitis and PCP, compared with heart transplant 
recipients. 
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TABLE 1. The diagnostic yield of BAL and TBB in solid organ transplantation 
Organ transplanted Reference Bronchoscopies Yield of Yield of Yield of BAL Yield of TBB 
(n> BAL TBB for specific for specific 
w> w> pathogen (%) pathogen (%) 
Heart 
Lung/Heart-lung 
Lung Baz (22) 
Lung/Heart-lung Chan (23) 
Kidney 
Kidney 
Kidney 
Kidney 
Liver 
Schulman (21) 39 63 46 
Sibley (73) 128 NA 78 
69 NA 48 
282 NA 67 
Cazzadori (4) 33 27 57 
Wallace (5) 7 85 NA 
Sternberg (6) 58 69 NA 
Willcox (74) 
Allen (75) 
28 NA* 45 
54 42 NA 
CMV (61) 
PCP (90) 
Asperg (75) 
TB (50) 
Bacterial (60) 
NA 
NA 
NA 
NA 
NA 
CMV (22) 
PCP (10) 
Bacterial (17) 
Nocardia (5) 
Legionella (7) 
Fungi (7) 
NA 
PCP (22) 
CMV (22) 
HSV (7) 
CMV (20) 
PCP (89) 
Asperg (22) 
TB (NA) 
CMV (3) 
PCP (3) 
Rejection (40) 
TB (0.7) 
CMV (11) 
Bacterial (9) 
Rejection (3 5) 
CMV (8) 
PCP (I) 
Bacterial (80) 
Rejection (28) 
NA 
NA 
NA 
NA 
NA 
Asperg, Aspergillosis: BMT, bone marrow transplant: CMV, cytomegalovirus: HSV, herpes simplex virus: NA, not available: 
PCP, Pneumocystis carinii pneumonitis: TB, tuberculosis. 
*Three patients underwent BAL which was positive. 
The high incidence of pulmonary graft rejection and 
bacterial infections within the first few weeks after 
transplantation, combined with the increased incidence of 
CMV pneumonitis during 2-6 months after transplanta- 
tion, has led to the use of routine surveillance broncho 
scopies during the first 2 years after transplantation in 
many centres. 
Fibre-optic bronchoscopy (FOB) 
FOB, with bronchoalveolar lavage (BAL) and transbron- 
chial biopsy (TBB), has played an important role in the 
diagnosis of pulmonary infiltrates in the immunocompro- 
mised patient in the last decade. This minimally invasive 
procedure allows the identification of pulmonary pathogens 
by sampling of bronchoalveolar lavage fluid or by direct 
histopathological examination of lung tissue. These 
methods facilitate sampling of the distal airways for 
cultures and cytological stains in an attempt to detect 
pathogens which reflect true distal airway infections, with 
much less risk of contamination by the oral and the upper 
airway flora, or by pathogens which merely colonize the 
upper airways (5). 
Several recent studies have attempted to evaluate the 
utility of BAL and TBB ‘in the immunocompromised host. 
In one retrospective study, the results of 157 bronchoscopic 
procedures, including both BAL and TBB, in 142 
immunosuppressed patients were reviewed (see Table 1) 
(6). All patients were treated with empirical wide-spectrum 
antibiotic therapy prior to performing FOB with no 
satisfactory response. In the specific group of kidney 
transplant patients, BAL had a diagnostic yield of 27%. 
However, the diagnostic yield of TBB was 57.5%. The total 
additional diagnostic yield of TBB to BAL was 33 %. These 
results suggest an important role for TBB in addition to 
BAL whenever there is no additional significant risk and no 
contraindications to performing TBB. 
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In another study (7) 19 bronchoscopies with BAL were 
performed to evaluate acute pulmonary infiltrates in a 
group of 18 immunocompromised patients, including AIDS 
patients, organ transplant patients and patients with solid 
tumours who were receiving cytotoxic chemotherapy. The 
bronchoscopy yielded a definite diagnosis in 72% of these 
patients. As a result of the overall findings at broncho- 
scopy, management was changed in 61% of the patients. In 
the group of patients who had BAL alone without an 
additional TBB, BAL was diagnostic in 75% of the patients 
and treatment management was consequently changed in 
42%. Retrospectively, these results showed that the initial 
clinical diagnosis was correct in only 56% of the patients 
and that empirical therapy would have lead to incorrect 
management in 28%. These results demonstrate the 
importance, of performing BAL at an early stage after 
presentation with pulmonary infiltrates. In this series 
however, performing TBB did not increase the diagnostic 
yield. In a subgroup of seven renal transplant recipients, the 
diagnostic yield of bronchoscopy was 85% and the 
sensitivity was 71%, but with no additional diagnostic 
value for TBB compared to BAL. 
In another retrospective analysis, Sternberg et al. (8) 
evaluated kidney transplant recipients who had a combina- 
tion of fever, pulmonary infiltrates and/or hypoxia. In 40% 
of these patients, the results of BAL lead to a change in the 
initial empirical antibiotic therapy. During the first 4 
months, CMV infection was common, as would be expected 
(2). In instances where co-infections were found, CMV was 
the most common pathogen. Of five patients with PCP, 
three patients had also findings of CMV pneumonitis on 
histological examination. Two additional patients had 
proven CMV viremia, with no evidence of CMV pneumo- 
nitis on lung biopsy. Thus this study demonstrates that 
TBB serves an important role in recognizing co-infection 
with bacterial infection and viral or parasitic pathogens. In 
cases where CMV iS isolated in BAL fluid or CMV viremia 
is detected, a definite diagnosis of CMV pneumonitis could 
be determined by identifying CMV inclusion bodies within 
the pulmonary parenchyma. 
The diagnostic utility of FOB 
for specific pathogens 
BACTERIAL PNEUMONIA 
Pneumonias caused by bacteria are most likely to occur 
within the first few weeks after transplantation (2), with 
lung and heart-lung transplantation patients being the 
most vulnerable (1,3). Transplant patients are more likely 
to be exposed to prolonged antibiotic treatment, be 
mechanically ventilated, have an in-dwelling nasogastric 
tube, or be given antacid therapy which elevates the 
stomach content pH: all well-known risk factors for 
nosocomial pneumonia. 
The most likely pathogens during the first weeks after 
transplant, include nosocomial pneumonias such as those 
caused by Gram-negative rods and Staphylococcus aureus. 
However, community pathogens such as Streptococcus 
Pneumoniae, Haemophilus Influenza and Mycoplasma pneu- 
moniae may also cause pneumonia in these patients and are 
still predominant in the later stages after the transplant 
procedure (l-3). Nosocomially acquired, Legionella infec- 
tions tend to occur in the first few weeks after transplant. 
Characteristically, they are accompanied by changes in 
mental status and gastrointestinal disturbances, with wide- 
spread chest radiographical changes (9). Nocardia, particu- 
larly asteroides, is increasingly recognized as a pathogen of 
the late stages after solid organ transplantation, particu- 
larly in renal transplant patients, with an incidence of about 
2% (10,ll). Besides the lungs, Nocardia has predilection for 
the skin and the brain. Interestingly, the incidence of 
nocardiosis in transplant patients has decreased since the 
use of cyclosporine compared with patients who received 
azathioprine in their immunosuppressive regimens (11). 
The routine administration of trimethoprim-sulphamethox- 
azole for prophylaxis in PCP has caused a reduction in 
bacterial and Nocardia infection, as noted after renal 
transplantation (14). Pseudomonas aeruginosa may be an 
important pathogen in early post-operatively stages and 
when lung transplantation is performed in patients with 
cystic fibrosis (12). Pseudomonas pneumonia is also seen at 
later stages after lung transplantation because of bronch- 
iectatic changes in the lung parenchyma secondary to 
chronic inflammatory processes such as bronchiolitis 
obliterans (13). Some authorities have advocated the 
regular use of quinolones after bone marrow transplant 
(BMT) as prophylaxis for bacterial infections, but this is 
not routinely used in solid organ transplant recipients (15). 
It may be difficult to determine the incidence of bacterial 
pneumonias in transplant patients due to the low yield of 
standard methods in identifying bacterial pathogens and 
the high frequency of bacterial colonization of the airways. 
In a large group of BMT patients, the specific bacterial 
pathogens were identified in 52% of the infectious episodes 
of bacterial pneumonias which could not be explained by 
opportunistic pathogens or non-infectious processes (16). 
FOB with quantitative protected specimen brushing 
(PSB) and BAL cultures may significantly aid in investigat- 
ing possible lower respiratory tract infections and distin- 
guish them from bacterial colonization. (17). It is 
acceptable to diagnose pneumonia if the cultures of 
specimens acquired by protected specimen brushing (PSB) 
and BAL have bacterial organism counts above a certain 
threshold concentration. [i.e. PSB > 103, and BAL > lo4 
colony forming units per ml (cfu/ml)] (17). PSB is a method 
with higher diagnostic specificity than simple sputum or 
sample is acquired by endotracheal aspiration for the 
diagnosis of nosocomial pneumonia and may better 
differentiate true infections from contamination. 
Several studies reviewing the results of bronchoscopic 
procedures in immunocompromised hosts including trans- 
plant patients have shown additional yield with BAL for 
diagnosing bacterial pneumonia (1X-20). The identification 
of Nocardia on a sputum smear requires a Ziehl-Nelsen 
stain but the culture may take 34 weeks to become 
positive (10). Legionella may be difficult to grow; however, 
examining respiratory secretions using the direct fluorescent 
antibody technique may allow a faster diagnosis (9). In 
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patients after heart transplantation, the sensitivity of BAL 
or PSB for identifying bacterial pathogens was 60% (21). 
Although FOB is useful for surveillance purposes after 
lung transplantation, the yield of the procedure is 
significantly increased when it is performed to evaluate a 
new infiltrate (8.7 vs. 0.6%) (22). A higher diagnostic 
advantage of PSB compared with BAL may result from a 
cautious policy followed by certain bronchoscopists, in 
which small amounts of fluid are used (24). These data 
support the use of BAL and PSB in evaluating transplant 
patients with new pulmonary infiltrates, as these methods 
improve the diagnostic yield of bacterial pneumonia and 
aid in differentiating bacteria from other non-bacterial 
pathogens. 
Pneumocystis carinii 
This is a common protozoan pathogen in immunocompro- 
mised patients in whom T-lymphocyte dysfunction is a 
dominant mechanism of immune dysfunction. PCP is the 
most common opportunistic pulmonary infection in AIDS 
(20) strongly suggesting that Pneumocystis carinii exists in 
a latent form in normal hosts and is reactivated as the host’s 
immunity level is reduced. In organ transplant patients, 
PCP is most likely to occur within the first 2-6 months after 
transplant (2). Of organ transplant patients, lung and 
heart-lung transplant patients are particularly vulnerable to 
PCP (3,4). Very effective prophylaxis for the prevention of 
PCP after organ transplantation has been achieved by 
providing patients with oral trimethoprim-sulphamethox- 
azole (24,2.5) and, to a lesser degree of success, with 
inhalations of pentamidine ( 26). 
The diagnostic utilities of BAL and TBB for the 
diagnosis of PCP are comparable (6,21). This may be 
explained by the fact that Pneumocystis carinii is present in 
the alveoli (27-29), unlike CMV which is an intracellular 
pathogen, thus the yield of BAL in detecting CMV is 
relatively lower than the yield of detecting Pneumocystis 
. . . camzz. 
VIRAL INFECTIONS 
The incidence of herpetic infections in organ transplant 
patients increases significantly 4 weeks after organ trans- 
plantation. Primary infections, or reactivation of herpes 
simplex virus and herpes varicella virus are commonly 
characterized by their diagnostic cutaneous rashes (1,2). 
CMV is an important pathogen of pneumonia in 
transplant patients. In bone marrow recipients, CMV may 
play an important role in immune reactions, such as 
the induction and propagation of graft .versus host disease 
in the lung (30-32) and the pathogenesis of bronchiolitis 
obliterans (30,33). Such an association between bronchio- 
litis obliterans and CMV infection has been suggested 
in lung transplant patients has not been clarified (3,34). 
In lung and heart-lung transplant patients, surveillance 
bronchoscopies are routinely performed within the first 4-6 
months in many centres (22,35) to allow early detection of 
graft rejection or CMV pneumonitis. The definite diagnosis 
of CMV pneumonitis may be determined on the basis of 
CMV inclusion bodies within the lung parenchyma, 
obtained through TBB (3), or the presence of cells with 
cytopathic changes typical of CMV within the BAL fluid. 
Growing CMV in BAL cultures is not considered definitely 
diagnostic of CMV pneumonitis because it may only 
reflect viral shedding or colonization of the respiratory 
tract with CMV (36). However, in BMT patients there 
are indications that obtaining CMV from BAL cultures 
may be predictive of an episode of CMV pneumonitis 
(37,38). In organ transplant patients, growing CMV 
from BAL culture has a low positive predictive value for 
CMV pneumonitis. On the other hand, the detection of 
CMV inclusion bodies or antigenaemia may be predictive 
(39,40). 
In general, BAL has a higher sensitivity than TBB for 
detecting CMV (23,41). The reported yield of BAL for the 
diagnosis of CMV pneumonitis is 1463% (7,21), while 
TBB yields diagnosis in 20% of cases (21). A recent study 
has suggested that negative BAL culture in a lung graft can 
exclude CMV pneumonitis in most cases (42). Confirmation 
of the CMV diagnosis may possible using centrifugation 
culture (43) the shell vial culture technique (44), mono- 
clonal antibodies (45) or the polymerase chain reaction 
(PCR) (46). Although these methods may be more sensitive 
and allow earlier diagnosis of CMV infection than BAL 
cytology, they have low specificity and thus their results 
must be interpreted cautiously. 
FUNGAL INFECTIONS 
Fungal infections play an important role in morbidity and 
mortality in organ transplant patients. Essentially, the 
diagnosis of fungal pneumonia requires the demonstration 
of the fungal pathogen within the lung parenchyma. The 
incidence of fungal pneumonia increases significantly in the 
first 2 months after transplant (1,2). The most important 
fungal pathogens are Candida and Aspevgillus. While 
Candida mostly involves the upper tracheobronchial tree, 
Aspevgillus is capable of dissemination and invading the 
whole lung (27). , 
Immunocompromised patients who are particularly 
susceptible to Aspergillus infections. are granulocytopenic 
patients or those with cellular immunodeficiency. BMT 
patients are at a very high risk for Aspergillus infection 
within the first month after transplant (30) and the infection 
carries a high mortality rate. Aspergihs is the most 
common cause of fungal pneumonia in liver and kidney 
transplant patients (1). Twenty-five per cent of patients may 
develop a pulmonary infection with Aspergillus after lung 
transplantation, with the majority of these infections 
occurring within the first month (3). Trachea-bronchial 
involvement with invasive Aspergillus may further extend to 
involve the cartilage of the main bronchi (47). 
Other fungal pathogens in immunocompromised patients 
include Cryptococcus neojiormans, which may cause 
concurrent pulmonary and central nervous system infec- 
tions (48), Mucormycosis, which is ,more likely to occur in 
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diabetic and acidotic kidney transplant patients (49): and 
endemic fungi such as Histoplasmosis and Blastomycosis 
which cause pulmonary infection with a later dissemination 
(2). 
It has been shown that, in diagnosing fungal pneumonia, 
TBB has an additional diagnostic yield of 29% relative to 
BAL stain and culture (50). In a mixed group of 
immunocompromised patients, BAL had a very high 
sensitivity but a relatively low specificity for the detection 
of Candida infection (51); however, the specificity of 
finding other fungi within BAL secretions is much higher, 
with a relatively lower sensitivity (52,53). These findings 
strongly suggest that the presence of Candida in the BAL 
fluid may represent colonization by Candida rather than 
infection or contamination of the endoscopic instrument as 
it passes through the upper respiratory tract. Using PSB 
can overcome this problem of contamination, thus sig- 
nificantly increasing the yield of FOB for detection of 
fungal infection (51). The diagnostic sensitivity and 
specificity of BAL may be enhanced by culturing the 
secretions for fungi (53). Unfortunately, in invasive fungal 
infection such as Aspergillus, BAL is not capable of 
demonstrating blood-vessel invasion (53); therefore there 
TBB still has an important role in the diagnosis of 
pulmonary fungal infections. In many cases where FOB 
cannot make the diagnosis of fungal pneumonia, an open 
lung biopsy is required. 
Mycobacferium tuberculosis (TB) and other 
mycobacferia 
TB in transplant patients mostly reflects the reactivation of 
an old TB focus. Another possible source of infection is the 
grafted organ (2). In the Western world, the incidence of 
mycobacterial infections after organ transplantation ap- 
proaches I%, compared to an incidence of 0.1% in the 
general population, with 30% of the infections caused by 
atypical mycobacteria (54). In endemic areas, the incidence 
of TB infection among renal transplant patients may rise to 
10-12’~ (55,56). Most of these infections occur at least 6 
months after transplantation (57). Although the lungs are 
the main target organ involved in TB, there is a higher 
incidence of extrapulmonary disease in these patients than 
in normal hosts (2). Atypical mycobacteria also tend to be 
disseminated and may primarily involve cutaneous and 
articular tissue rather than presenting as a primary 
pulmonary infection (58). 
The recent resurgence of TB with the AIDS epidemic has 
lead to a re-evaluation of the diagnostic yield of broncho- 
scopy for the diagnosis of TB. In HIV-positive patients, 
acid-fast smears of specimens collected by BAL were 
positive in 19% of cases, while an equal percentage of 
transbronchial biopsies had granulomata within pulmonary 
tissue with a minimal percentage having positive acid-fast 
tissue staining (59). Culture of FOB specimens in the same 
study yielded Mycobacteria in 62% of the BAL specimens 
and 52% of the TBB specimens. Notably, the yield of 
sputum cultures was 89%. Nevertheless, using FOB in these 
patients proved to be important as it allowed early 
diagnosis of TB through histological findings on TBB. 
Interestingly, similar findings regarding the yield of FOB 
for the diagnosis of TB in non-immunocompromised 
patients have been described (60) and suggest that sputum 
smear and culture are more reliable and cost-effective 
whenever sputum can be obtained (61). Generally the yield 
of TBB in the diagnosis of TB is higher than that of BAL. 
In a mixed subgroup group of immunocompromised 
patients only 50% patients had a BAL diagnostic for TB. 
(7). Newer diagnostic methods based on PCR technology 
may allow who had TB diagnosed by TBB, earlier diagnosis 
of TB in transplant patients who are iess likely to have a 
high load of TB bacilli, thus enabling early diagnosis by 
positive microscopic examination or growth on culture 
(62,63). In patients who are suspected clinically to have TB 
but who have negative results of acid-fast smear, a positive 
PCR result would encourage the initiation of anti- 
tuberculous therapy at least until the final results of 
mycobacterial culture are available (63). However, it must 
be kept in mind that most of the PCR kits available today 
have a relatively low specificity. 
To summarize, there is an important role for TBB in 
patients suspected of having TB, in whom BAL fluid 
staining and culture may be inadequate for diagnosis. 
However, whenever sufficient sputum specimens can be 
obtained, these samples must be examined adequately as 
they have a high diagnostic yield and may omit the need for 
FOB. If FOB is performed, then the procedure should 
include TBB. 
Complications 
TBB is associated with a relatively low incidence of 
complications. The risk of complications after TBB in 
immunocompromised hosts does not exceed that of the 
general population. Unfortunately, thrombocytopaenia, 
which is common in BMT patients, and uraemia in renal 
transplant patients, prevent the performance of TBB in 
many cases because of the risk of bleeding. 
In one study, only four out of 106 (3.7%) patients had 
complications, of whom three had pneumothorax and one 
an intrapulmonary haemorrhage, with no known coagulo- 
pathy (5). In patients with pulmonary hypertension, 
intrapulmonary haemorrhage may be an important con- 
cern. In a recently described series of heart transplant 
patients who underwent TBB, only 15% had minimal 
intrapulmonary haemorrhages with volumes of less than 25 
ml (21). 
OPEN LUNG BIOPSY (OLB) 
In cases where FOB is not diagnostic; OLB should be 
considered. This method is considered the gold-standard 
for evaluation of lung infiltrates in the immunocompro- 
mised host. OLB is performed in up to one-third of these 
patients due to failure of previous less invasive diagnostic 
procedures, or due to rapid deterioration in the general 
state of the patient despite an adequate trial of empirical 
therapy. In a mixed group of 61 patients, OLB led to a 
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definite diagnosis in 34 (56%) (64). Of these patients, 36% 
were immunosuppressed and OLB, while diagnostic in 59% 
of cases, led to a change of treatment in 77% of the 
patients. 
In a recent. retrospective review of the utility of OLB in a 
mixed group of patients, the subgroup which seemed to 
benefit most OLB were immunosuppressed patients (with 
only one patient after organ transplantation), as they had a 
high yield with the highest rate of unexpected diagnoses 
leading to a change in therapy (65). Unfortunately, this 
benefit was offset by a high mortality rate, which reflects the 
worse prognosis of this group of patients, resulting from 
their underlying conditions. 
OLB may lead to a change in the therapeutic strategy in 
one-third of lung transplant patients (66). The results from 
OLB in lung transplant patients suggest that it may be more 
important, and more likely to lead to a change in 
therapeutic strategy, when it is used for pulmonary 
infections, which appear at a later stage after transplant, 
compared with infections occurring within the first month 
(66). In heart transplant recipients, OLB was diagnostic in 
78% of the patients in one series (67). 
Earlier studies have cast doubts on whether OLB is able 
to improve survival of patients with pulmonary infiltrates, 
probably reflecting the severity of the condition of these 
patients (68,69). The presence of several pathogens 
simultaneously may be partly responsible for this bad 
outcome (69). The general rate of complications of OLB is 
ll-18% (64,70,71), which result mainly from surgical 
technique. Such complications include bronchopleural 
fistulas and persistent air leak, which may require 
prolonged mechanical ventilation (64). There was no 
increase in the rate of infections related to the procedure 
in immunocompromised patients compared with normal 
hosts despite their vulnerability to such infections (64). 
Despite evidence that OLB in immunocompromised 
patients is very helpful in investigating opportunistic 
infections, especially those occurring at a late stage after 
transplant, it is still considered an invasive method which 
carries a certain risk for morbidity and mortality. Never- 
theless, OLB remains the final diagnostic resort whenever 
FOB fails to provide a proper diagnosis in transplant 
patients with pulmonary infiltrates. 
Conclusion 
The data presented were reflect the importance of early 
FOB in patients after organ transplantation, as this may 
lead to the early identification of pathogens in patients 
presenting with pulmonary infiltrates and fever. 
Due to the wide variety of possible infectious and non- 
infectious causes of pulmonary infiltrates in solid organ 
transplant patients, we recommend early performance of 
FOB, including TBB, whenever there is no contraindica- 
tion. Such an approach will enable the prompt treatment of 
life-threatening complications and will protect the patient 
from unnecessary measures, which carry a high risk of 
morbidity. 
FOB and TBB are relatively safe with a low rate of 
complications in solid organ transplant patients, and carry 
no excess rate of morbidity relative to non-transplant or 
non-immunocompromised patients. Even in critically ill 
transplant patients, there is a favourable risk-benefit ratio 
for performing FOB, due to the diagnostic information 
provided by BAL and TBB. 
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